Altogether, those data indicated that oxytetracycline selectively suppressed the LCSC (AFP+/CD133+ HCC) population and LCSC properties and suggested oxytetracycline as an appropriate drug to prevent HCC recurrence and to overcome chemoresistance. This evidence concerns the gene PROM1 and hepatocellular carcinoma.